DE60219005D1 - Feste pharmazeutische formulierung enthaltend modafinil - Google Patents

Feste pharmazeutische formulierung enthaltend modafinil

Info

Publication number
DE60219005D1
DE60219005D1 DE60219005T DE60219005T DE60219005D1 DE 60219005 D1 DE60219005 D1 DE 60219005D1 DE 60219005 T DE60219005 T DE 60219005T DE 60219005 T DE60219005 T DE 60219005T DE 60219005 D1 DE60219005 D1 DE 60219005D1
Authority
DE
Germany
Prior art keywords
pharmaceutical formulation
formulation containing
solid pharmaceutical
modafinil
containing modafinil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60219005T
Other languages
English (en)
Other versions
DE60219005T2 (de
Inventor
Vincent Corvari
George Grandolfi
Alpa Parikh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26852708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60219005(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Application granted granted Critical
Publication of DE60219005D1 publication Critical patent/DE60219005D1/de
Publication of DE60219005T2 publication Critical patent/DE60219005T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60219005T 2001-05-25 2002-05-23 Modafinil umfassende feste pharmazeutische Formulierungen Expired - Lifetime DE60219005T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29369501P 2001-05-25 2001-05-25
US293695P 2001-05-25
US155913 2002-05-23
US10/155,913 US7297346B2 (en) 2001-05-25 2002-05-23 Pharmaceutical formulations of modafinil
PCT/US2002/016369 WO2002096401A1 (en) 2001-05-25 2002-05-24 Solid pharmaceutical formulations comprising modafinil

Publications (2)

Publication Number Publication Date
DE60219005D1 true DE60219005D1 (de) 2007-05-03
DE60219005T2 DE60219005T2 (de) 2007-12-13

Family

ID=26852708

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60219005T Expired - Lifetime DE60219005T2 (de) 2001-05-25 2002-05-23 Modafinil umfassende feste pharmazeutische Formulierungen

Country Status (20)

Country Link
US (1) US7297346B2 (de)
EP (1) EP1397127B8 (de)
JP (1) JP4443119B2 (de)
KR (1) KR100911779B1 (de)
CN (1) CN1318026C (de)
AT (1) ATE357228T1 (de)
AU (1) AU2002318155B8 (de)
BR (1) BRPI0210085B8 (de)
CA (1) CA2448456C (de)
DE (1) DE60219005T2 (de)
ES (1) ES2281527T3 (de)
HK (1) HK1061652A1 (de)
IL (1) IL158959A (de)
MX (1) MXPA03010705A (de)
MY (1) MY129376A (de)
NO (1) NO328805B1 (de)
NZ (1) NZ530040A (de)
TW (1) TWI321475B (de)
WO (1) WO2002096401A1 (de)
ZA (1) ZA200309978B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168946A1 (de) 2000-07-27 2010-03-31 Teva Pharmaceutical Industries Ltd Kirstalline Form von Modafinil und Verfahren zu deren Herstellung
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
CN1684666A (zh) * 2002-07-25 2005-10-19 兰贝克赛实验室有限公司 制备莫达非尼口服剂型的方法
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
FR2849029B1 (fr) * 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
CA2420180A1 (en) * 2003-02-28 2004-08-28 Bernard Charles Sherman Tablets comprising modafinil
CA2519117C (en) * 2003-03-17 2010-03-02 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
UA94380C2 (ru) * 2003-09-18 2011-05-10 Сефалон, Інк. Фармацевтические композиции модафинила с модифицированным высвобождением
US8153159B2 (en) 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
BRPI0612440A2 (pt) * 2005-04-08 2010-11-23 New River Pharmaceuticals Inc composição farmacêutica e uso de um profármaco de anfetamina
US20070048373A1 (en) * 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
KR101431711B1 (ko) * 2008-05-07 2014-08-21 삼성전자 주식회사 발광 장치 및 발광 시스템의 제조 방법, 상기 방법을이용하여 제조한 발광 장치 및 발광 시스템
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
EP2649187B1 (de) 2010-12-08 2017-11-22 Codexis, Inc. Biokatalysatoren und verfahren zur synthese von armodafinil
EP2730274B1 (de) * 2010-12-21 2015-08-05 Akzo Nobel Chemicals International B.V. Instantpulver für wässrige kosmetische und pharmazeutische Anwendungen
FR2987266B1 (fr) 2012-02-28 2014-12-19 Debregeas Et Associes Pharma Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1570994A (en) 1923-11-20 1926-01-26 William A Cook Spring-forming die
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
GB9225492D0 (en) * 1992-12-05 1993-01-27 Glaxo Group Ltd Amine derivatives
US5843347A (en) 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
FR2702968B1 (fr) * 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
FR2706767B1 (de) 1993-06-22 1995-09-08 Lafon Labor
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
AU9062998A (en) * 1997-09-11 1999-03-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
SI20624A (sl) 1998-12-18 2002-02-28 Abbott Laboratories Formulacija divalproeks natrija za kontrolirano sproščanje
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6346548B1 (en) 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) * 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US20010034373A1 (en) 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
US6670358B2 (en) 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides

Also Published As

Publication number Publication date
JP4443119B2 (ja) 2010-03-31
BRPI0210085B1 (pt) 2020-11-10
CN1318026C (zh) 2007-05-30
US20030022940A1 (en) 2003-01-30
AU2002318155B2 (en) 2007-03-01
ZA200309978B (en) 2005-05-25
NO20035211D0 (no) 2003-11-24
CN1511031A (zh) 2004-07-07
KR20040005986A (ko) 2004-01-16
EP1397127A1 (de) 2004-03-17
NZ530040A (en) 2005-11-25
CA2448456C (en) 2010-07-27
BRPI0210085B8 (pt) 2021-07-20
IL158959A0 (en) 2004-05-12
MY129376A (en) 2007-03-30
IL158959A (en) 2010-06-30
AU2002318155B8 (en) 2008-05-15
NO328805B1 (no) 2010-05-18
WO2002096401A1 (en) 2002-12-05
HK1061652A1 (en) 2004-09-30
CA2448456A1 (en) 2002-12-05
EP1397127B1 (de) 2007-03-21
BRPI0210085A (pt) 2004-06-29
EP1397127B8 (de) 2008-02-20
ATE357228T1 (de) 2007-04-15
JP2004532863A (ja) 2004-10-28
ES2281527T3 (es) 2007-10-01
TWI321475B (en) 2010-03-11
DE60219005T2 (de) 2007-12-13
US7297346B2 (en) 2007-11-20
MXPA03010705A (es) 2004-05-27
KR100911779B1 (ko) 2009-08-12

Similar Documents

Publication Publication Date Title
ATE357228T1 (de) Feste pharmazeutische formulierung enthaltend modafinil
SE0102315D0 (sv) Compounds
AP1770A (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their sythesis.
GB0004128D0 (en) Novel compounds
SE0301700D0 (sv) Novel compounds
SE0101675D0 (sv) Novel composition
ATE433447T1 (de) Pyrimiidinverbindungen
SE0104140D0 (sv) Novel Compounds
SE0103836D0 (sv) Novel compounds
CY1109465T1 (el) Νεες φαρμακευτικες φαρμακοτεχνικες μορφες μονταφινιλης
SE0302139D0 (sv) Novel compounds
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
SE0102716D0 (sv) Novel compounds
SE9804212D0 (sv) Compounds
SE0101038D0 (sv) Novel compounds
SE0101322D0 (sv) Novel compounds
MY134026A (en) ?-carboline derivatives and its pharmaceutical use against depression and anxiety
SE0303280D0 (sv) Novel compounds
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
DE60201074D1 (en) Pyrazolopyridinderivate
SE0202693D0 (sv) Compounds
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
AR033910A1 (es) Nuevas formulaciones farmaceuticas de moda-finil

Legal Events

Date Code Title Description
8364 No opposition during term of opposition